PMID- 30894350
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20190408
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 364
DP  - 2019 Mar 20
TI  - The BMJ Awards 2019: Diabetes Team of the Year.
PG  - l1232
LID - 10.1136/bmj.l1232 [doi]
FAU - Wise, Jacqui
AU  - Wise J
AD  - London, UK.
LA  - eng
PT  - Journal Article
DEP - 20190320
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:01
CRDT- 2019/03/22 06:00
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:01 [medline]
AID - 10.1136/bmj.l1232 [doi]
PST - epublish
SO  - BMJ. 2019 Mar 20;364:l1232. doi: 10.1136/bmj.l1232.

PMID- 30429124
OWN - NLM
STAT- MEDLINE
DCOM- 20190321
LR  - 20190321
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 363
DP  - 2018 Nov 14
TI  - Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events:
      nationwide register based cohort study.
PG  - k4365
LID - 10.1136/bmj.k4365 [doi]
AB  - OBJECTIVE: To assess the association between the use of sodium glucose
      cotransporter 2 (SGLT2) inhibitors and seven serious adverse events of current
      concern. DESIGN: Register based cohort study. SETTING: Sweden and Denmark from
      July 2013 to December 2016. PARTICIPANTS: A propensity score matched cohort of 17
      213 new users of SGLT2 inhibitors (dapagliflozin, 61%; empagliflozin, 38%;
      canagliflozin, 1%) and 17 213 new users of the active comparator, glucagon-like
      peptide 1 (GLP1) receptor agonists. MAIN OUTCOME MEASURES: The primary outcomes
      were lower limb amputation, bone fracture, diabetic ketoacidosis, acute kidney
      injury, serious urinary tract infection, venous thromboembolism, and acute
      pancreatitis, as identified from hospital records. Hazard ratios and 95%
      confidence intervals were estimated by using Cox proportional hazards models.
      RESULTS: Use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was
      associated with an increased risk of lower limb amputation (incidence rate 2.7 v 
      1.1 events per 1000 person years, hazard ratio 2.32, 95% confidence interval 1.37
      to 3.91) and diabetic ketoacidosis (1.3 v 0.6, 2.14, 1.01 to 4.52) but not with
      bone fracture (15.4 v 13.9, 1.11, 0.93 to 1.33), acute kidney injury (2.3 v 3.2, 
      0.69, 0.45 to 1.05), serious urinary tract infection (5.4 v 6.0, 0.89, 0.67 to
      1.19), venous thromboembolism (4.2 v 4.1, 0.99, 0.71 to 1.38) or acute
      pancreatitis (1.3 v 1.2, 1.16, 0.64 to 2.12). CONCLUSIONS: In this analysis of
      nationwide registers from two countries, use of SGLT2 inhibitors, as compared
      with GLP1 receptor agonists, was associated with an increased risk of lower limb 
      amputation and diabetic ketoacidosis, but not with other serious adverse events
      of current concern.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not
      already granted under a licence) please go to
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Ueda, Peter
AU  - Ueda P
AUID- ORCID: http://orcid.org/0000-0002-3275-8743
AD  - Clinical Epidemiology Division, Department of Medicine, Solna, Eugeniahemmet, T2,
      Karolinska University Hospital, 17176 Stockholm, Sweden peter.ueda@ki.se.
FAU - Svanstrom, Henrik
AU  - Svanstrom H
AD  - Clinical Epidemiology Division, Department of Medicine, Solna, Eugeniahemmet, T2,
      Karolinska University Hospital, 17176 Stockholm, Sweden.
AD  - Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
FAU - Melbye, Mads
AU  - Melbye M
AD  - Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
AD  - Department of Medicine, Stanford University School of Medicine, Stanford, CA,
      USA.
FAU - Eliasson, Bjorn
AU  - Eliasson B
AD  - Department of Molecular and Clinical Medicine, Institute of Medicine, University 
      of Gothenburg, Gothenburg, Sweden.
FAU - Svensson, Ann-Marie
AU  - Svensson AM
AD  - The Swedish National Diabetes Register, Vastra Gotalandsregionen, Gothenburg,
      Sweden.
FAU - Franzen, Stefan
AU  - Franzen S
AD  - The Swedish National Diabetes Register, Vastra Gotalandsregionen, Gothenburg,
      Sweden.
FAU - Gudbjornsdottir, Soffia
AU  - Gudbjornsdottir S
AD  - Department of Molecular and Clinical Medicine, Institute of Medicine, University 
      of Gothenburg, Gothenburg, Sweden.
AD  - The Swedish National Diabetes Register, Vastra Gotalandsregionen, Gothenburg,
      Sweden.
FAU - Hveem, Kristian
AU  - Hveem K
AD  - KG Jebsen Center for Genetic Epidemiology, Department of Public Health and
      Nursing, Faculty of Medicine and Health Science, Norwegian University of Science 
      and Technology, Trondheim, Norway.
AD  - HUNT Research Center, Faculty of Medicine, Norwegian University of Science and
      Technology, Levanger, Norway.
FAU - Jonasson, Christian
AU  - Jonasson C
AD  - KG Jebsen Center for Genetic Epidemiology, Department of Public Health and
      Nursing, Faculty of Medicine and Health Science, Norwegian University of Science 
      and Technology, Trondheim, Norway.
AD  - HUNT Research Center, Faculty of Medicine, Norwegian University of Science and
      Technology, Levanger, Norway.
FAU - Pasternak, Bjorn
AU  - Pasternak B
AD  - Clinical Epidemiology Division, Department of Medicine, Solna, Eugeniahemmet, T2,
      Karolinska University Hospital, 17176 Stockholm, Sweden.
AD  - Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20181114
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0
      (2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-t
      riol)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - HDC1R2M35U (empagliflozin)
SB  - AIM
SB  - IM
CIN - BMJ. 2019 Feb 6;364:l547. PMID: 30728150
MH  - Adult
MH  - Amputation/statistics & numerical data
MH  - Benzhydryl Compounds/*adverse effects
MH  - Canagliflozin/*adverse effects
MH  - Cohort Studies
MH  - Denmark/epidemiology
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Diabetic Ketoacidosis/epidemiology
MH  - Female
MH  - Fractures, Bone/epidemiology
MH  - Glucosides/*adverse effects
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Pancreatitis/epidemiology
MH  - Propensity Score
MH  - Sodium-Glucose Transporter 2 Inhibitors/*adverse effects
MH  - Sweden/epidemiology
MH  - Urinary Tract Infections/epidemiology
MH  - Venous Thromboembolism/epidemiology
PMC - PMC6233755
COIS- Competing interests: All authors have completed the Unified Competing Interest
      form at www.icmje.org/coi_disclosure.pdf (available on request from the
      corresponding author) and have the following declarations: CJ reports personal
      fees from Pfizer and Bayer outside the submitted work; BE reports personal fees
      from Amgen, AstraZeneca, Boerhringer Ingelheim, Eli Lilly, Merck Sharp and Dohme,
      Mundipharma, Navamedic, Novo Nordisk, and RLS Global outside the submitted work, 
      and grants from Sanofi outside the submitted work; and SG reports personal fees
      and research grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck
      Sharp and Dohme, Novo Nordisk, and Sanofi outside of the submitted work. The
      other authors did not have any potential conflicts to report.
EDAT- 2018/11/16 06:00
MHDA- 2019/03/22 06:00
CRDT- 2018/11/16 06:00
PHST- 2018/11/16 06:00 [entrez]
PHST- 2018/11/16 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - 10.1136/bmj.k4365 [doi]
PST - epublish
SO  - BMJ. 2018 Nov 14;363:k4365. doi: 10.1136/bmj.k4365.

PMID- 30897245
OWN - NLM
STAT- Publisher
LR  - 20190406
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Mar 21
TI  - Relationship between corneal confocal microscopy and markers of peripheral nerve 
      structure and function in Type 2 diabetes.
LID - 10.1111/dme.13952 [doi]
AB  - AIMS: To investigate changes in corneal nerve morphology in Type 2 diabetes and
      to establish relationships between in vivo corneal confocal microscopy and
      markers of peripheral nerve structure and function. PARTICIPANTS AND METHODS: We 
      recruited 57 participants with Type 2 diabetes and 26 healthy controls of similar
      age and sex distribution. We also recruited a disease control group of 54
      participants with Type 1 diabetes. All participants were assessed for distal
      symmetrical polyneuropathy using the Total Neuropathy Score. In vivo corneal
      confocal microscopy was used to assess corneal nerve fibre length, corneal nerve 
      fibre density, corneal nerve branch density and inferior whorl length. Peripheral
      nerve structure was assessed using median nerve ultrasonography. Large fibre
      function was assessed according to median nerve axonal excitability. Small fibre 
      function was assessed using Sudoscan(TM) and the Survey of Autonomic Symptoms.
      RESULTS: Corneal nerve fibre length, fibre density and branch density and
      inferior whorl length were significantly lower in individuals with Type 2
      diabetes compared to controls (P<0.001 for all). In the Type 2 diabetes cohort,
      correlations were observed between neuropathy severity and corneal nerve fibre
      density (P=0.004), corneal nerve branch density (P=0.003), corneal nerve fibre
      length (P=0.002) and inferior whorl length (P=0.01). Significant correlations
      were observed between corneal confocal outcomes and axonal excitability
      measurements. No association was found between corneal confocal microscopy and
      median nerve cross-sectional area, Sudoscan measurements or the Survey of
      Autonomic Symptoms. CONCLUSIONS: This study demonstrated significant changes in
      corneal nerves in individuals with Type 2 diabetes. Reductions in corneal nerve
      measures correlated with increasing neuropathy severity. Associations were found 
      between corneal confocal microscopy and markers of voltage-gated potassium
      channel function.
CI  - (c) 2019 Diabetes UK.
FAU - Yan, A
AU  - Yan A
AUID- ORCID: https://orcid.org/0000-0002-1173-6051
AD  - Prince of Wales Clinical School, University of New South Wales, Sydney, NSW,
      Australia.
FAU - Issar, T
AU  - Issar T
AUID- ORCID: https://orcid.org/0000-0002-8323-6048
AD  - Prince of Wales Clinical School, University of New South Wales, Sydney, NSW,
      Australia.
FAU - Tummanapalli, S S
AU  - Tummanapalli SS
AUID- ORCID: https://orcid.org/0000-0002-2114-1422
AD  - School of Optometry and Vision Science, University of New South Wales, Sydney,
      NSW, Australia.
FAU - Markoulli, M
AU  - Markoulli M
AD  - School of Optometry and Vision Science, University of New South Wales, Sydney,
      NSW, Australia.
FAU - Kwai, N C G
AU  - Kwai NCG
AD  - School of Medical Sciences, University of New South Wales, Sydney, NSW,
      Australia.
FAU - Poynten, A M
AU  - Poynten AM
AD  - Department of Endocrinology, Prince of Wales Hospital, Sydney, NSW, Australia.
FAU - Krishnan, A V
AU  - Krishnan AV
AD  - Prince of Wales Clinical School, University of New South Wales, Sydney, NSW,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20190321
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/18 00:00 [accepted]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
PHST- 2019/03/22 06:00 [entrez]
AID - 10.1111/dme.13952 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Mar 21. doi: 10.1111/dme.13952.

PMID- 30897242
OWN - NLM
STAT- Publisher
LR  - 20190403
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Mar 21
TI  - Foot deformity in a man with Type 2 diabetes.
LID - 10.1111/dme.13950 [doi]
FAU - Taylor, K
AU  - Taylor K
AD  - Abertawe Bro Morgannwg University Health Board, Singleton Hospital, Swansea, UK.
FAU - Bain, S C
AU  - Bain SC
AUID- ORCID: https://orcid.org/0000-0001-8519-4964
AD  - Abertawe Bro Morgannwg University Health Board, Singleton Hospital, Swansea, UK.
LA  - eng
PT  - Journal Article
DEP - 20190321
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/18 00:00 [accepted]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
PHST- 2019/03/22 06:00 [entrez]
AID - 10.1111/dme.13950 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Mar 21. doi: 10.1111/dme.13950.

PMID- 30897241
OWN - NLM
STAT- Publisher
LR  - 20190411
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Mar 21
TI  - Prospective association between late evening food consumption and risk of
      prediabetes and diabetes: the Whitehall II cohort study.
LID - 10.1111/dme.13951 [doi]
AB  - AIMS: We examined whether late evening food consumption was prospectively
      associated with the risk of developing prediabetes or diabetes in a large
      observational study of individuals with normoglycaemia. METHODS: Participants
      were 2642 men and women with normoglycaemia (HbA1c < 39 mmol/mol; < 5.7%) from
      the Whitehall II study. Time of last eating episode (TLEE) before the examination
      day was assessed at baseline. We studied the associations of TLEE with 5-year
      changes in HbA1c and risk of developing prediabetes or diabetes (HbA1c >/= 39
      mmol/mol; >/= 5.7%). Potential heterogeneity in the association between TLEE and 
      prediabetes or diabetes was examined using recursive partitioning modelling for
      time-to-event outcomes. RESULTS: There was a tendency of an overall association
      of TLEE with change in HbA1c but with little effect size [beta per 1-h increase
      in TLEE = 0.2 mmol/mol, 95% CI -0.0 to 0.3 (0.01%, -0.00 to 0.03); P = 0.055] and
      no association with the risk of developing prediabetes/diabetes (risk ratio per
      1-h increase in TLEE = 1.03, 95% CI 0.94 to 1.13; P = 0.511). According to the
      recursive partitioning modelling, women with HbA1c </= 36 mmol/mol and TLEE after
      21:00 had a 1.51 times (95% CI 1.16 to 1.93) higher 5-year risk of developing
      prediabetes or diabetes than those having their TLEE between 16:00 and 21:00
      (35.4% vs. 23.5%; P = 0.003). CONCLUSIONS: There was no overall association of
      TLEE with the development of prediabetes or diabetes in the Whitehall II
      population. However, explorative analyses suggested that eating late in the
      evening was associated with increased risk of developing prediabetes/diabetes
      among women with good glycaemic control. Whether restricting late evening food
      consumption is effective and feasible for the prevention of Type 2 diabetes needs
      testing in randomized controlled trials.
CI  - (c) 2019 Diabetes UK.
FAU - Faerch, K
AU  - Faerch K
AUID- ORCID: https://orcid.org/0000-0002-6127-0448
AD  - Clinical Epidemiology, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Quist, J S
AU  - Quist JS
AD  - Clinical Epidemiology, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
AD  - Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Hulman, A
AU  - Hulman A
AD  - Department of Public Health, Aarhus University, Aarhus, Denmark.
AD  - Danish Diabetes Academy, Odense, Denmark.
FAU - Witte, D R
AU  - Witte DR
AD  - Department of Public Health, Aarhus University, Aarhus, Denmark.
AD  - Danish Diabetes Academy, Odense, Denmark.
FAU - Tabak, A G
AU  - Tabak AG
AD  - 1st Department of Internal Medicine, Faculty of Medicine, Semmelweis University, 
      Budapest, Hungary.
FAU - Brunner, E J
AU  - Brunner EJ
AD  - Department of Epidemiology & Public Health, University College London, London,
      UK.
FAU - Kivimaki, M
AU  - Kivimaki M
AD  - Department of Epidemiology & Public Health, University College London, London,
      UK.
FAU - Jorgensen, M E
AU  - Jorgensen ME
AD  - Clinical Epidemiology, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
AD  - National Institute of Public Health, Southern Denmark University, Copenhagen,
      Denmark.
FAU - Panda, S
AU  - Panda S
AD  - Salk Institute for Biological Studies, La Jolla, CA, USA.
FAU - Vistisen, D
AU  - Vistisen D
AD  - Clinical Epidemiology, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
LA  - eng
GR  - K013351/UK Medical Research Council
GR  - RG/13/2/30098/British Heart Foundation/United Kingdom
GR  - R01HL36310/US National Institutes of Health
GR  - R01AG013196/US National Institutes of Health
GR  - Novo Nordisk Foundation
GR  - Danish Diabetes Academy
GR  - K013351/Medical Research Council/United Kingdom
GR  - R024227/Medical Research Council/United Kingdom
GR  - K013351/NordForsk
GR  - R024227/NordForsk
GR  - 311492/Academy of Finland
GR  - R01 HL036310/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20190321
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/18 00:00 [accepted]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
PHST- 2019/03/22 06:00 [entrez]
AID - 10.1111/dme.13951 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Mar 21. doi: 10.1111/dme.13951.

PMID- 30889281
OWN - NLM
STAT- Publisher
LR  - 20190319
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Mar 19
TI  - Prevalence of diabetes in Poland: a combined analysis of national databases.
LID - 10.1111/dme.13949 [doi]
AB  - AIMS: To assess the number of people with diabetes in Poland using combined
      national sources and to evaluate the usefulness of data from an insurance system 
      for epidemiological purposes. METHODS: The data were collected from four sources:
      1) 2013 all-billing records of the national insurance system comprising people of
      all age groups undergoing procedures or receiving services in primary healthcare,
      specialist practices and hospitals and also those receiving drugs; 2) an
      epidemiological study, NATPOL, that involved the assessment of people with
      undiagnosed diabetes; 3) the RECEPTOmetr Sequence study on prescriptions; and 4) 
      regional child diabetes registries. RESULTS: In 2013, 1.76 million people (0.98
      million women and 0.79 million men) had medical consultations (coded E10-E14) and
      2.13 million people (1.19 million women and 0.94 million men) purchased drugs or 
      strip tests for diabetes. A total of 0.04 million people who used medical
      services did not buy drugs. In total, the number of people with diabetes in the
      insurance system was 2.16 million (1.21 million women and 0.95 million men),
      which corresponds to 6.1% (95% CI 6.11-6.14) of women and 5.1% (95% CI 5.12-5.14)
      of men. Including undiagnosed cases, the total number of people with diabetes in 
      Poland was 2.68 million in 2013. CONCLUSION: The estimated prevalence of diabetes
      (diagnosed and undiagnosed cases) in Poland is 6.97%. Data from the national
      insurance system with full coverage of the population can be treated as a
      reliable source of information on diseases with well-defined diagnosis and
      treatment methods, combined with an assessment of the number of undiagnosed
      individuals. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
FAU - Topor-Madry, R
AU  - Topor-Madry R
AD  - Institute of Public Health, Faculty of Health Sciences, Jagiellonian University
      Medical College, Krakow.
FAU - Wojtyniak, B
AU  - Wojtyniak B
AD  - National Institute of Public Health - National Institute of Hygiene, Warsaw.
FAU - Strojek, K
AU  - Strojek K
AD  - Department of Internal Diseases, Diabetology and Cardiometabolic Diseases, School
      of Medicine with the Division of Dentistry in Zabrze, Medical University of
      Silesia, Katowice.
FAU - Rutkowski, D
AU  - Rutkowski D
AD  - National Health Fund, Warsaw.
FAU - Boguslawski, S
AU  - Boguslawski S
AD  - PEX PharmaSequence LLC.
FAU - Ignaszewska-Wyrzykowska, A
AU  - Ignaszewska-Wyrzykowska A
AD  - Department of Preventive Medicine and Medical Education, Medical University of
      Gdansk, Gdansk.
FAU - Jarosz-Chobot, P
AU  - Jarosz-Chobot P
AD  - Department of Children's Diabetology, Medical University of Silesia.
FAU - Czech, M
AU  - Czech M
AD  - Medical University in Warsaw, Warsaw.
FAU - Kozierkiewicz, A
AU  - Kozierkiewicz A
AD  - Jaspers, Warsaw.
FAU - Chlebus, K
AU  - Chlebus K
AD  - Department of Cardiology, Clinical Center of Cardiology, Medical University of
      Gdansk, Gdansk.
FAU - Jedrzejczyk, T
AU  - Jedrzejczyk T
AD  - Department of Preventive Medicine and Medical Education, Medical University of
      Gdansk, Gdansk.
FAU - Mysliwiec, M
AU  - Mysliwiec M
AD  - Chair of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk,
      Gdansk, Poland.
FAU - Polanska, J
AU  - Polanska J
AD  - Data Mining Group, Silesian University of Technology, Gliwice.
FAU - Wysocki, M J
AU  - Wysocki MJ
AD  - National Institute of Public Health - National Institute of Hygiene, Warsaw.
FAU - Zdrojewski, T
AU  - Zdrojewski T
AD  - Department of Preventive Medicine and Medical Education, Medical University of
      Gdansk, Gdansk.
LA  - eng
PT  - Journal Article
DEP - 20190319
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/03/20 06:00
MHDA- 2019/03/20 06:00
CRDT- 2019/03/20 06:00
PHST- 2019/03/20 06:00 [entrez]
PHST- 2019/03/20 06:00 [pubmed]
PHST- 2019/03/20 06:00 [medline]
AID - 10.1111/dme.13949 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Mar 19. doi: 10.1111/dme.13949.

PMID- 30894392
OWN - NLM
STAT- In-Data-Review
LR  - 20190321
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 4
DP  - 2019 Apr
TI  - In This Issue of Diabetes.
PG  - 679-680
LID - 10.2337/db19-ti04 [doi]
LA  - eng
PT  - Editorial
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - 68/4/679 [pii]
AID - 10.2337/db19-ti04 [doi]
PST - ppublish
SO  - Diabetes. 2019 Apr;68(4):679-680. doi: 10.2337/db19-ti04.

PMID- 30885990
OWN - NLM
STAT- Publisher
LR  - 20190319
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2019 Mar 18
TI  - Ameliorating Methylglyoxal-Induced Progenitor Cell Dysfunction for Tissue Repair 
      in Diabetes.
LID - db180933 [pii]
LID - 10.2337/db18-0933 [doi]
AB  - Patient-derived progenitor cell (PC) dysfunction is severely impaired in
      diabetes, but the molecular triggers that contribute to mechanisms of PC
      dysfunction are not fully understood. Methylglyoxal (MGO) is one of the highly
      reactive dicarbonyl species formed during hyperglycemia. We hypothesize that the 
      MGO scavenger glyoxalase 1 (GLO1) reverses bone marrow-derived progenitor cell
      (BMPCs) dysfunction through augmenting the activity of an important endoplasmic
      reticulum (ER) stress sensor, inositol-requiring enzyme 1alpha (IRE1alpha),
      resulting in improved diabetic wound healing. BMPCs were isolated from adult male
      db/db type-2 diabetic mice and their healthy corresponding control db/+ mice. MGO
      at the concentration of 10microM induced immediate and severe BMPC dysfunction,
      including impaired network formation, migration, proliferation, and increased
      apoptosis, which were rescued by adenovirus-mediated GLO1 overexpression.
      IRE1alpha expression and activation in BMPCs were significantly attenuated by MGO
      exposure but rescued by GLO1 overexpression. MGO can diminish IRE1alpha RNase
      activity by directly binding to IRE1alpha in vitro In a diabetic mouse cutaneous 
      wound model in vivo, cell therapies using diabetic cells with GLO1 overexpression
      remarkably accelerated wound closure by enhancing angiogenesis, compared with
      diabetic control cell therapy. Augmenting tissue GLO1 expression by
      adenovirus-mediated gene transfer or with the small-molecule inducer
      trans-resveratrol and hesperetin formulation also improved wound closure and
      angiogenesis in diabetic mice. In conclusion, our data suggest that GLO1 rescues 
      BMPC dysfunction and facilitates wound healing in diabetic animals, at least
      partly through preventing MGO-induced impairment of IRE1alpha expression and
      activity. Our results provide important knowledge for the development of novel
      therapeutic approaches targeting MGO to improve PC-mediated angiogenesis and
      tissue repair in diabetes.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Li, Hainan
AU  - Li H
AD  - Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and
      Health Sciences.
FAU - O'Meara, Megan
AU  - O'Meara M
AD  - Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and
      Health Sciences.
FAU - Zhang, Xiang
AU  - Zhang X
AD  - Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and
      Health Sciences.
FAU - Zhang, Kezhong
AU  - Zhang K
AD  - Center for Molecular Medicine and Genetics.
AD  - Department of Immunology and Microbiology.
FAU - Seyoum, Berhane
AU  - Seyoum B
AD  - Division of Endocrinology, School of Medicine.
FAU - Yi, Zhengping
AU  - Yi Z
AD  - Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and
      Health Sciences.
AD  - Integrated Biosciences.
FAU - Kaufman, Randal J
AU  - Kaufman RJ
AD  - Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery
      Institute, La Jolla, CA.
FAU - Monks, Terrence J
AU  - Monks TJ
AD  - Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and
      Health Sciences.
AD  - Integrated Biosciences.
FAU - Wang, Jie-Mei
AU  - Wang JM
AD  - Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and
      Health Sciences; jiemei.wang@wayne.edu.
AD  - Center for Molecular Medicine and Genetics.
AD  - Cardiovascular Research Institute; Wayne State University, Detroit, MI.
LA  - eng
PT  - Journal Article
DEP - 20190318
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/03/20 06:00
MHDA- 2019/03/20 06:00
CRDT- 2019/03/20 06:00
PHST- 2018/08/31 00:00 [received]
PHST- 2019/03/08 00:00 [accepted]
PHST- 2019/03/20 06:00 [entrez]
PHST- 2019/03/20 06:00 [pubmed]
PHST- 2019/03/20 06:00 [medline]
AID - db18-0933 [pii]
AID - 10.2337/db18-0933 [doi]
PST - aheadofprint
SO  - Diabetes. 2019 Mar 18. pii: db18-0933. doi: 10.2337/db18-0933.

PMID- 30894391
OWN - NLM
STAT- In-Data-Review
LR  - 20190407
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - Response to Comment on Lacy et al. Long-term Glycemic Control and Dementia Risk
      in Type 1 Diabetes. Diabetes Care 2018;41:2339-2345.
PG  - e69
LID - 10.2337/dci18-0065 [doi]
FAU - Lacy, Mary E
AU  - Lacy ME
AUID- ORCID: http://orcid.org/0000-0002-8814-8725
AD  - Department of Epidemiology and Biostatistics, University of California, San
      Francisco, San Francisco, CA mary.lacy2@ucsf.edu.
AD  - Division of Research, Kaiser Permanente, Oakland, CA.
FAU - Gilsanz, Paola
AU  - Gilsanz P
AUID- ORCID: http://orcid.org/0000-0002-7635-381X
AD  - Division of Research, Kaiser Permanente, Oakland, CA.
FAU - Karter, Andrew J
AU  - Karter AJ
AUID- ORCID: http://orcid.org/0000-0001-5527-316X
AD  - Division of Research, Kaiser Permanente, Oakland, CA.
FAU - Quesenberry, Charles P
AU  - Quesenberry CP
AD  - Division of Research, Kaiser Permanente, Oakland, CA.
FAU - Pletcher, Mark J
AU  - Pletcher MJ
AD  - Department of Epidemiology and Biostatistics, University of California, San
      Francisco, San Francisco, CA.
FAU - Whitmer, Rachel A
AU  - Whitmer RA
AD  - Department of Epidemiology and Biostatistics, University of California, San
      Francisco, San Francisco, CA.
AD  - Division of Research, Kaiser Permanente, Oakland, CA.
AD  - Division of Epidemiology, Public Health Sciences, University of California Davis 
      School of Medicine, Davis, CA.
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
PMC - PMC6429631
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PMCR- 2020/04/01 00:00
PHST- 2020/04/01 00:00 [pmc-release]
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - 42/4/e69 [pii]
AID - 10.2337/dci18-0065 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):e69. doi: 10.2337/dci18-0065.

PMID- 30894390
OWN - NLM
STAT- In-Data-Review
LR  - 20190321
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - Comment on Lacy et al. Long-term Glycemic Control and Dementia Risk in Type 1
      Diabetes. Diabetes Care 2018;41:2339-2345.
PG  - e68
LID - 10.2337/dc18-2467 [doi]
FAU - Medrano-De-Avila, Carolina
AU  - Medrano-De-Avila C
AD  - Endocrinology Division, Department of Internal Medicine, University Hospital "Dr.
      Jose E. Gonzalez," Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.
FAU - Castillo-Castro, Carolina
AU  - Castillo-Castro C
AUID- ORCID: http://orcid.org/0000-0002-1758-7835
AD  - Endocrinology Division, Department of Internal Medicine, University Hospital "Dr.
      Jose E. Gonzalez," Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.
FAU - Lavalle-Gonzalez, Fernando J
AU  - Lavalle-Gonzalez FJ
AUID- ORCID: http://orcid.org/0000-0001-8820-5366
AD  - Endocrinology Division, Department of Internal Medicine, University Hospital "Dr.
      Jose E. Gonzalez," Universidad Autonoma de Nuevo Leon, Monterrey, Mexico
      drfernandolavalle@hotmail.com.
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - 42/4/e68 [pii]
AID - 10.2337/dc18-2467 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):e68. doi: 10.2337/dc18-2467.

PMID- 30894389
OWN - NLM
STAT- In-Data-Review
LR  - 20190321
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - Response to Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of 
      Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care
      2018;41:1579-1589.
PG  - e66-e67
LID - 10.2337/dci18-0066 [doi]
FAU - Umpierrez, Guillermo E
AU  - Umpierrez GE
AUID- ORCID: http://orcid.org/0000-0002-3252-5026
AD  - Division of Endocrinology, Metabolism and Lipids, Emory University School of
      Medicine, Atlanta, GA geumpie@emory.edu.
FAU - Klonoff, David C
AU  - Klonoff DC
AD  - Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA.
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - 42/4/e66 [pii]
AID - 10.2337/dci18-0066 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):e66-e67. doi: 10.2337/dci18-0066.

PMID- 30894388
OWN - NLM
STAT- In-Data-Review
LR  - 20190321
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin
      Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care
      2018;41:1579-1589.
PG  - e64-e65
LID - 10.2337/dc18-2455 [doi]
FAU - Grammes, Jennifer
AU  - Grammes J
AUID- ORCID: http://orcid.org/0000-0002-5894-6734
AD  - Health Psychology, Johannes Gutenberg University, Mainz, Germany
      jegramme@uni-mainz.de.
AD  - Diabetes Technology Working Group, German Diabetes Association, Ulm, Germany.
FAU - Kuestner, Eva
AU  - Kuestner E
AD  - Diabetes Technology Working Group, German Diabetes Association, Ulm, Germany.
FAU - Heinemann, Lutz
AU  - Heinemann L
AD  - Diabetes Technology Working Group, German Diabetes Association, Ulm, Germany.
AD  - Science-Consulting in Diabetes GmbH, Neuss, Germany.
FAU - Kubiak, Thomas
AU  - Kubiak T
AD  - Health Psychology, Johannes Gutenberg University, Mainz, Germany.
AD  - Diabetes Technology Working Group, German Diabetes Association, Ulm, Germany.
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - 42/4/e64 [pii]
AID - 10.2337/dc18-2455 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):e64-e65. doi: 10.2337/dc18-2455.

PMID- 30894387
OWN - NLM
STAT- In-Data-Review
LR  - 20190321
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - Response to Comment on Cheng et al. Trends and Disparities in Cardiovascular
      Mortality Among U.S. Adults With and Without Self-Reported Diabetes, 1988-2015.
      Diabetes Care 2018;41:2306-2315.
PG  - e63
LID - 10.2337/dci18-0057 [doi]
FAU - Cheng, Yiling J
AU  - Cheng YJ
AUID- ORCID: http://orcid.org/0000-0002-5053-0814
AD  - Division of Diabetes Translation, National Center for Chronic Disease Prevention 
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
      ycheng@cdc.gov.
FAU - Imperatore, Giuseppina
AU  - Imperatore G
AD  - Division of Diabetes Translation, National Center for Chronic Disease Prevention 
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
FAU - Albright, Ann L
AU  - Albright AL
AD  - Division of Diabetes Translation, National Center for Chronic Disease Prevention 
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
FAU - Gregg, Edward W
AU  - Gregg EW
AUID- ORCID: http://orcid.org/0000-0003-2381-6822
AD  - Division of Diabetes Translation, National Center for Chronic Disease Prevention 
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - 42/4/e63 [pii]
AID - 10.2337/dci18-0057 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):e63. doi: 10.2337/dci18-0057.

PMID- 30894386
OWN - NLM
STAT- In-Data-Review
LR  - 20190321
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - Comment on Cheng et al. Trends and Disparities in Cardiovascular Mortality Among 
      U.S. Adults With and Without Self-Reported Diabetes, 1988-2015. Diabetes Care
      2018;41:2306-2315.
PG  - e62
LID - 10.2337/dc18-2175 [doi]
FAU - Manicardi, Valeria
AU  - Manicardi V
AD  - Diabetes Registry, Azienda Unita Sanitaria Locale - IRCCS Reggio Emilia, Reggio
      Emilia, Italy.
FAU - Vicentini, Massimo
AU  - Vicentini M
AUID- ORCID: http://orcid.org/0000-0002-0227-2523
AD  - Epidemiology Unit, Azienda Unita Sanitaria Locale - IRCCS Reggio Emilia, Reggio
      Emilia, Italy massimo.vicentini@ausl.re.it.
FAU - Ballotari, Paola
AU  - Ballotari P
AD  - Osservatorio Epidemiologico, ATS Val Padana, Mantua, Italy.
FAU - Venturelli, Francesco
AU  - Venturelli F
AD  - Epidemiology Unit, Azienda Unita Sanitaria Locale - IRCCS Reggio Emilia, Reggio
      Emilia, Italy.
AD  - Specialization School of Hygiene and Preventive Medicine, Department of
      Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio
      Emilia, Modena, Italy.
AD  - Clinical and Experimental Medicine PhD Program, University of Modena and Reggio
      Emilia, Modena, Italy.
FAU - Giorgi Rossi, Paolo
AU  - Giorgi Rossi P
AD  - Epidemiology Unit, Azienda Unita Sanitaria Locale - IRCCS Reggio Emilia, Reggio
      Emilia, Italy.
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - 42/4/e62 [pii]
AID - 10.2337/dc18-2175 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):e62. doi: 10.2337/dc18-2175.

PMID- 30894384
OWN - NLM
STAT- In-Data-Review
LR  - 20190406
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - Erratum. Impact of lifestyle and metformin interventions on the risk of
      progression to diabetes and regression to normal glucose regulation in overweight
      or obese people with impaired glucose regulation. Diabetes Care
      2017;40:1668-1677.
PG  - 701
LID - 10.2337/dc19-er04 [doi]
FAU - Herman, William H
AU  - Herman WH
FAU - Pan, Qing
AU  - Pan Q
FAU - Edelstein, Sharon L
AU  - Edelstein SL
FAU - Mather, Kieren J
AU  - Mather KJ
FAU - Perreault, Leigh
AU  - Perreault L
FAU - Barrett-Connor, Elizabeth
AU  - Barrett-Connor E
FAU - Dabelea, Dana M
AU  - Dabelea DM
FAU - Horton, Edward
AU  - Horton E
FAU - Kahn, Steven E
AU  - Kahn SE
FAU - Knowler, William C
AU  - Knowler WC
FAU - Lorenzo, Carlos
AU  - Lorenzo C
FAU - Pi-Sunyer, Xavier
AU  - Pi-Sunyer X
FAU - Venditti, Elizabeth
AU  - Venditti E
FAU - Ye, Wen
AU  - Ye W
CN  - Diabetes Prevention Program Research Group
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EFR - Diabetes Care. 2017 Dec;40(12):1668-1677. PMID: 29021207
PMC - PMC6429634
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - 42/4/701 [pii]
AID - 10.2337/dc19-er04 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):701. doi: 10.2337/dc19-er04.

PMID- 30894380
OWN - NLM
STAT- In-Data-Review
LR  - 20190321
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - In This Issue of Diabetes Care.
PG  - 497-498
LID - 10.2337/dc19-ti04 [doi]
LA  - eng
PT  - Editorial
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - 42/4/497 [pii]
AID - 10.2337/dc19-ti04 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):497-498. doi: 10.2337/dc19-ti04.

PMID- 30894365
OWN - NLM
STAT- Publisher
LR  - 20190321
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 20
TI  - Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1
      Diabetes: The DCCT/EDIC Study.
LID - dc181613 [pii]
LID - 10.2337/dc18-1613 [doi]
AB  - OBJECTIVE: The Diabetes Control and Complications Trial (DCCT)/Epidemiology of
      Diabetes Interventions and Complications (EDIC) study has demonstrated the major 
      role of hyperglycemia as a risk factor for clinical cardiovascular outcomes in
      type 1 diabetes (T1D). We assessed whether and to what extent the effect of
      glycemia is mediated by other established cardiovascular disease (CVD) risk
      factors. RESEARCH DESIGN AND METHODS: In the DCCT, 1,441 participants were
      randomized to receive either intensive or conventional diabetes therapy. The EDIC
      observational follow-up study enrolled 96% of the surviving DCCT cohort with 94% 
      of the survivors still actively participating after more than 27 years of
      follow-up. Mediation of the effect of glycemia, as captured by HbA1c, on the
      subsequent CVD risk was quantified using the relative change in the CVD risk
      associated with HbA1c between models without and with the potential mediator.
      RESULTS: Adjusted for age, only a few factors (e.g., pulse, triglycerides,
      albumin excretion rate) explained more than 10% of the effect of glycemia on CVD 
      risk when considered individually. In multivariable models, these traditional
      risk factors together mediated up to approximately 50% of the effect of glycemia 
      on the risk of CVD. However, the association between HbA1c and the risk of CVD
      remained highly significant even after adjustment for these risk factors.
      CONCLUSIONS: While HbA1c is associated with many traditional CVD risk factors,
      its association with these factors alone cannot explain its effects on risk of
      CVD. Consequently, aggressive management of traditional nonglycemic CVD risk
      factors, coupled with aggressive glycemic management, is indicated for
      individuals with type 1 diabetes.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Bebu, Ionut
AU  - Bebu I
AUID- ORCID: http://orcid.org/0000-0002-4944-7968
AD  - Biostatistics Center, The George Washington University, Rockville, MD
      ibebu@bsc.gwu.edu.
FAU - Braffett, Barbara H
AU  - Braffett BH
AUID- ORCID: http://orcid.org/0000-0002-2184-9754
AD  - Biostatistics Center, The George Washington University, Rockville, MD.
FAU - Orchard, Trevor J
AU  - Orchard TJ
AD  - University of Pittsburgh, Pittsburgh, PA.
FAU - Lorenzi, Gayle M
AU  - Lorenzi GM
AD  - University of California, San Diego, San Diego, CA.
FAU - Lachin, John M
AU  - Lachin JM
AUID- ORCID: http://orcid.org/0000-0001-9838-2841
AD  - Biostatistics Center, The George Washington University, Rockville, MD.
CN  - and the DCCT/EDIC Research Group
LA  - eng
PT  - Journal Article
DEP - 20190320
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/22 06:00
MHDA- 2019/03/22 06:00
CRDT- 2019/03/22 06:00
PHST- 2018/07/27 00:00 [received]
PHST- 2019/02/27 00:00 [accepted]
PHST- 2019/03/22 06:00 [entrez]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
AID - dc18-1613 [pii]
AID - 10.2337/dc18-1613 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 20. pii: dc18-1613. doi: 10.2337/dc18-1613.

PMID- 30885955
OWN - NLM
STAT- Publisher
LR  - 20190319
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 18
TI  - The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue
      Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With
      8-Week Treatment in Type 2 Diabetes Patients.
LID - dc181569 [pii]
LID - 10.2337/dc18-1569 [doi]
AB  - OBJECTIVE: The aim of this study was to investigate tissue-specific effects of
      dapagliflozin on insulin sensitivity and liver and body fat in patients with type
      2 diabetes. RESEARCH DESIGN AND METHODS: This randomized, double-blind, parallel 
      group, placebo-controlled study recruited 32 patients with type 2 diabetes.
      Enrolled patients were to have HbA1c 6.5-10.5% (48-91 mmol/mol) and >/=3 months
      of stable treatment with metformin, dipeptidyl peptidase 4 inhibitor, or their
      combination. Patients were randomized 1:1 to receive 10 mg dapagliflozin or
      placebo daily for 8 weeks. Before and after the intervention, tissue insulin
      sensitivity was measured using [(18)F]-fluorodeoxyglucose and positron emission
      tomography (PET) during hyperinsulinemic-euglycemic clamp. Liver proton density
      fat fraction (PDFF) and adipose tissue volumes were assessed using MRI, and blood
      biomarkers were analyzed. RESULTS: After 8 weeks, glycemic control was improved
      by dapagliflozin (placebo-corrected change in HbA1c -0.39%, P < 0.01), but
      whole-body glucose uptake was not increased (P = 0.90). Tissue-specific
      insulin-stimulated glucose uptake did not change in skeletal muscle, liver,
      myocardium, or white and brown adipose tissue, and endogenous glucose production 
      remained unaffected. However, there were significant placebo-corrected decreases 
      in liver PDFF (-3.74%, P < 0.01), liver volume (-0.10 L, P < 0.05), visceral
      adipose tissue volume (-0.35 L, P < 0.01), interleukin-6 (-1.87 pg/mL, P < 0.05),
      and N-terminal prohormone of brain natriuretic peptide (-96 ng/L, P = 0.03).
      CONCLUSIONS: In this study, 8 weeks of treatment with dapagliflozin reduced liver
      PDFF and the volume of visceral adipose tissue in obese patients with type 2
      diabetes. Although glycemic control was improved, no effect on tissue-level
      insulin sensitivity was observed.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Latva-Rasku, Aino
AU  - Latva-Rasku A
AD  - Turku PET Centre, University of Turku, Turku, Finland.
FAU - Honka, Miikka-Juhani
AU  - Honka MJ
AUID- ORCID: http://orcid.org/0000-0001-9875-5863
AD  - Turku PET Centre, University of Turku, Turku, Finland.
FAU - Kullberg, Joel
AU  - Kullberg J
AD  - Antaros Medical AB, Molndal, Sweden.
AD  - Section of Radiology, Department of Surgical Sciences, Uppsala University,
      Uppsala, Sweden.
FAU - Mononen, Nina
AU  - Mononen N
AD  - Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular 
      Research Center-Tampere, Faculty of Medicine and Life Sciences, University of
      Tampere, Tampere, Finland.
FAU - Lehtimaki, Terho
AU  - Lehtimaki T
AD  - Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular 
      Research Center-Tampere, Faculty of Medicine and Life Sciences, University of
      Tampere, Tampere, Finland.
FAU - Saltevo, Juha
AU  - Saltevo J
AD  - Central Finland Central Hospital, Jyvaskyla, Finland, and Terveystalo, Jyvaskyla,
      Finland.
FAU - Kirjavainen, Anna K
AU  - Kirjavainen AK
AD  - Turku PET Centre, University of Turku, Turku, Finland.
FAU - Saunavaara, Virva
AU  - Saunavaara V
AD  - Turku PET Centre, University of Turku, Turku, Finland.
FAU - Iozzo, Patricia
AU  - Iozzo P
AUID- ORCID: http://orcid.org/0000-0001-6443-7074
AD  - Institute of Clinical Physiology, National Research Council (IFC-CNR), Pisa,
      Italy.
FAU - Johansson, Lars
AU  - Johansson L
AD  - Antaros Medical AB, Molndal, Sweden.
FAU - Oscarsson, Jan
AU  - Oscarsson J
AD  - AstraZeneca Gothenburg, Molndal, Sweden.
FAU - Hannukainen, Jarna C
AU  - Hannukainen JC
AUID- ORCID: http://orcid.org/0000-0002-8692-4049
AD  - Turku PET Centre, University of Turku, Turku, Finland.
FAU - Nuutila, Pirjo
AU  - Nuutila P
AUID- ORCID: http://orcid.org/0000-0001-9597-338X
AD  - Turku PET Centre, University of Turku, Turku, Finland pirjo.nuutila@utu.fi.
AD  - Department of Endocrinology, Turku University hospital, Turku, Finland.
LA  - eng
PT  - Journal Article
DEP - 20190318
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/20 06:00
MHDA- 2019/03/20 06:00
CRDT- 2019/03/20 06:00
PHST- 2018/07/21 00:00 [received]
PHST- 2019/02/04 00:00 [accepted]
PHST- 2019/03/20 06:00 [entrez]
PHST- 2019/03/20 06:00 [pubmed]
PHST- 2019/03/20 06:00 [medline]
AID - dc18-1569 [pii]
AID - 10.2337/dc18-1569 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 18. pii: dc18-1569. doi: 10.2337/dc18-1569.

PMID- 30885954
OWN - NLM
STAT- Publisher
LR  - 20190319
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 18
TI  - Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, 
      Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
LID - dc181427 [pii]
LID - 10.2337/dc18-1427 [doi]
AB  - OBJECTIVE: Soluble urokinase plasminogen activator receptor (suPAR) is an
      important inflammatory biomarker implicated in endothelial and podocyte
      dysfunction. However, suPAR's predictive qualities for complications in type 1
      diabetes have yet to be determined. We investigated the prognostic value of suPAR
      for the development of cardiovascular events, decline in renal function, and
      mortality in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: We
      included 667 patients with type 1 diabetes with various degrees of albuminuria in
      a prospective study. End points were cardiovascular events (cardiovascular death,
      nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral 
      arterial interventions), estimated glomerular filtration rate (eGFR) decline
      >/=30%, progression from lower to higher albuminuric state, development of
      end-stage renal disease (ESRD), and mortality. Follow-up was 5.2-6.2 years.
      Results were adjusted for known risk factors. Hazard ratios (HRs) are presented
      per doubling of suPAR with 95% CI. Relative integrated discrimination (rIDI) was 
      calculated. RESULTS: suPAR was available in all participants; median
      (interquartile range) was 3.4 ng/mL (2.7-4.5). The adjusted HR (95% CI) for
      cardiovascular events (n = 94), progression in albuminuria (n = 36), eGFR decline
      (n = 93), ESRD (n = 23), and mortality (n = 58) were 3.13 (1.96-5.45, P < 0.001),
      1.27 (0.51-3.19, P = 0.61), 2.93 (1.68-5.11, P < 0.001), 2.82 (0.73-11.9, P =
      0.13), and 4.13 (1.96-8.69, P < 0.001), respectively. rIDI was significant for
      cardiovascular events (22.6%, P < 0.001), eGFR decline (14.4%, P < 0.001), and
      mortality (23.9%, P < 0.001). CONCLUSIONS: In patients with type 1 diabetes and a
      broad range of albuminuria, a higher level of suPAR is a significant and
      independent risk factor for cardiovascular events, decline in eGFR >/=30%, and
      mortality. In addition, suPAR contributes significantly to discrimination for the
      end points.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Rotbain Curovic, Viktor
AU  - Rotbain Curovic V
AUID- ORCID: http://orcid.org/0000-0002-4270-6701
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark
      viktor.rotbain.curovic@regionh.dk.
FAU - Theilade, Simone
AU  - Theilade S
AUID- ORCID: http://orcid.org/0000-0002-1151-8951
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Winther, Signe A
AU  - Winther SA
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Tofte, Nete
AU  - Tofte N
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Eugen-Olsen, Jesper
AU  - Eugen-Olsen J
AD  - Clinical Research Centre, Copenhagen University Hospital Hvidovre, Hvidovre,
      Denmark.
FAU - Persson, Frederik
AU  - Persson F
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Hansen, Tine W
AU  - Hansen TW
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Jeppesen, Jorgen
AU  - Jeppesen J
AD  - Department of Medicine, Amager Hvidovre Hospital, Glostrup, Denmark.
AD  - University of Copenhagen, Copenhagen, Denmark.
FAU - Rossing, Peter
AU  - Rossing P
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
AD  - University of Copenhagen, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20190318
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/20 06:00
MHDA- 2019/03/20 06:00
CRDT- 2019/03/20 06:00
PHST- 2018/07/04 00:00 [received]
PHST- 2019/02/25 00:00 [accepted]
PHST- 2019/03/20 06:00 [entrez]
PHST- 2019/03/20 06:00 [pubmed]
PHST- 2019/03/20 06:00 [medline]
AID - dc18-1427 [pii]
AID - 10.2337/dc18-1427 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 18. pii: dc18-1427. doi: 10.2337/dc18-1427.

PMID- 30885953
OWN - NLM
STAT- Publisher
LR  - 20190319
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 18
TI  - Sex Differences in Treatment With ACE Inhibitors and Angiotensin Receptor
      Blockers in Type 1 Diabetes Patients.
LID - dc182542 [pii]
LID - 10.2337/dc18-2542 [doi]
FAU - Mollsten, Anna
AU  - Mollsten A
AUID- ORCID: http://orcid.org/0000-0002-8451-1603
AD  - Pediatrics, Department of Clinical Sciences, Umea University, Umea, Sweden
      anna.mollsten@umu.se.
FAU - Toppe, Cecilia
AU  - Toppe C
AD  - Pediatrics, Department of Clinical Sciences, Umea University, Umea, Sweden.
AD  - Department of Internal Medicine, Ryhov County Hospital, Jonkoping, Sweden.
FAU - Eeg-Olofsson, Katarina
AU  - Eeg-Olofsson K
AD  - Department of Medicine, Sahlgrenska University Hospital, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Lind, Torbjorn
AU  - Lind T
AD  - Pediatrics, Department of Clinical Sciences, Umea University, Umea, Sweden.
LA  - eng
PT  - Letter
DEP - 20190318
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/20 06:00
MHDA- 2019/03/20 06:00
CRDT- 2019/03/20 06:00
PHST- 2018/12/12 00:00 [received]
PHST- 2019/01/29 00:00 [accepted]
PHST- 2019/03/20 06:00 [entrez]
PHST- 2019/03/20 06:00 [pubmed]
PHST- 2019/03/20 06:00 [medline]
AID - dc18-2542 [pii]
AID - 10.2337/dc18-2542 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 18. pii: dc18-2542. doi: 10.2337/dc18-2542.